Emergence of tet(A) and blaKPC-2 co-carrying plasmid from a ST11 hypervirulent Klebsiella pneumoniae isolate in patient's gut

Worldwide, reports of carbapenem-resistant Klebsiella pneumoniae (CRKP) are increasing, and CRKP infections are often associated with high morbidity and mortality. Tigecycline is among the few drugs of choice for the treatment of carbapenem-resistant bacterial infections. However, tigecycline-resistant CRKP isolates have been reported in several regions with detection rates of 9.1 –14.5% [1,2]. The mechanisms conferring tigecycline resistance in K. pneumoniae are not well characterized or elucidated.
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Letter to the Editor Source Type: research